neglecteddiseasesmayofferimmensetherapeutic use. Seems to bewillingness to invest rather considerable 90 sums of money Aidan Hollis into the support of such research but the problem of, as one is this investment an obstacle assigns. This chapter examined some requests for new incentives for neglected disease research: during it, represents, hangs theAdvancedPurchaseContract plans and theTransferable plans of the right at the mental property with the alternatively released reward request together. The alternatively released reward request lets a reward, which is based on the measured therapeutic effect of its inventive drug receive to enterprises, against the opened offer, the zero-costs licenses of the production and the sale of the drug. The advanced PurchaseContract systemis, which limited a version of this request to specific drugs, or which vaccines, which have technical characteristics, which can be defined clearly, before the product is developed, where the therapeutic effect of the drug is accepted, based on its pre-determined technical characteristics. There are the compromises, which are implicit between these two systems: the main use advanced sales contract request is that its much more limited range a small of the financing permits. The transferable request of the rights at the mental property, which is used in BioShield II, is also a kind alternatively released reward system, butwith a to a high degree ineffective systemfor, financing andwithout awell definedmethodology for the determination of the size of the reward raises. Its main attraction is that it possibly offers large rewards to pharmaceutical enterprises without new taxes. So large pharmaceutical enterprises and self-interested politicians can find them attractive; Consumers of the drugs are however probable by it to be damaged. No request without errors is obvious, and the pragmatic forward of way can have to be continued, financing apportionable, in order to refer research investments, to public-private partnerships and to systematic purchases of the existing drugs. Each possible request for the new incentivesmechanisms, which recompense enterprises for successful development of the drugs for neglected diseases, must show convincingly that it is a better use of the money than those tried and tested methods. When such gives, it an urgent need at the much more careful analysis of the different requests, which in this chapter and in reasonable weighing of their earnings/services and defects, particularly compared with the direct financing ways, how government grants for research are discussed, which tighten at present most financing.